Eneficial effects in a variety of illness models. On the other hand, most mammalian cells secret modest amount of EV, that is a limitation for development of therapeutics. Hence, the subsequent generation of EV-mimetic vesicles made by ULK2 Storage & Stability serial extrusion of cells produces higher quantity of vesicles, and could possibly be a lot easier to scale up for therapeutic developments. In this study we aimed to test the efficacy of EV-mimetic vesicles derived from human adipose-derived stem cells (hASCs) on rat osteoarthritis (OA) model. Procedures: hASC-derived EV-mimetic vesicles (CDV) have been made by serial extrusions of cells via filters. The CDVs have been characterized by transmission electron microscopy (TEM), nanoparticle analysis method (NTA), and western blot and flow cytometry. CDVs have been injected into the joints within a MIA-induced osteoarthritis (OA) rat model. Improvement of pain soon after CDV injections was assessed by paw withdrawal threshold and weight bearing, whereas the joint destruction was evaluated by histology. We also estimated the effects of CDV on proliferation and migration of human chondrocytes in vitro by cell-counting and scratch assays. Results: The CDV have been 5050 nm in diameter and carried many EV-associated STAT3 Species tetraspanins (CD63, CD9, CD81). CDV-treated OA mice had decreased paw withdrawal and was extra weight bearing 17 days just after therapy than PBS-treated. Additional, histology showed reduced joint defects at 24 days. CDV-treated OA models displayed substantial improvement in pawJOURNAL OF EXTRACELLULAR VESICLESwithdrawal behaviour and weight bearing analysis. Similarly, chondrocyte migration and proliferation had been enhanced by CDV inside a dose-dependent manner. Summary/Conclusion: This study demonstrates for the initial time the efficacy of hASC EV-mimetic vesicles in OA model. Most interestingly we have confirmed that hASC EV-mimetic vesicles can enhance pain and regenerate defected cartilage. These final results assistance the concept that a possible application of hASC EVmimetic is osteoarthritis, by providing CDV locally into affected joints.Funding: This project is sponsored by NIH grant R01DE027404 as well as the Osteology Foundation Advanced Researcher award.PF08.Exosomes secreted throughout chondrogenic differentiation of human adipose-derived stem cells for osteoarthritis remedy Ye eun Yuna, Woo Sung Kima, Hyun-A Parkb, Su Yeon Kimb and Yong Woo Choc Department of Chemical Engineering, Hanyang University, Ansan, Republic of Korea; bExostemtech,Inc., Ansan, Republic of Korea; cHanyang University, Ansan, Republic of KoreaaPF08.Natural and synthetic biomaterial mediated delivery of Mesenchymal Stem Cell derived exosomes Chun-Chieh Huanga, Miya Kanazawab, Praveen Gajendrareddyc and Sriram Ravindranaa University of Illinois at Chicago, Chicago, IL, USA; bUIC College of Dentistry, Oral Biology, Chicago, IL, USA; cUniversity of Illinois, Chicago, Chicago, IL, USAIntroduction: Mesenchymal stem cell (MSC) derived exosomes are versatile agents that possess immunomodulatory and regenerative properties. However, systemic delivery of natural or engineered MSC exosomes lacks site-specificity and may trigger ectopic effects. Thus, biomaterial-mediated site-specific delivery of exosomes is significant. As exosomal membranes are subsets in the plasma membrane. We hypothesized that MSC exosomes can bound to extracellular matrix proteins along with the home is usually used as a delivery technique. Solutions: To test this hypothesis, we evaluated the binding and delivery kinetics of MSC exosomes to a.